Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add filters








Year range
1.
Medicina (B.Aires) ; 67(1): 71-81, jan.-fev. 2007. ilus, graf, tab
Article in Spanish | LILACS | ID: lil-464750

ABSTRACT

La altura, fascinante laboratorio natural de investigación médica, provee resultados con importantes implicancias para la comprensión de enfermedades que afectan a millones de personas que viven en ella, asi como para el tratamiento de enfermedades ligadas a la hipoxemia en pacientes que viven en baja altitud. El edema pulmonar de altura (EPA) es una entidad que pone en peligro la vida y que ocurre en sujetos predispuestos pero sanos. Esto permite estudiar los mecanismos subyacentes del edema pulmonar en humanos, sin la presencia de factores que presten a la confusión como enfermedades concomitantes. El EPA resulta de la conjunción de dos defectos mayores: acumulación de líquido en el espacio alveolar debido a una hipertensión pulmonar hipóxica exagerada, y alteración en la eliminación del mismo por un defecto en el transporte transepitelial alveolar de sodio. En esta revisión, describimos brevemente las características clínicas y revisaremos este novedoso concepto. Proveemos evidencia experimental de como la síntesis alterada de óxido nítrico y/o la disminución de su biodisponibilidad representan el defecto central que predispone a la vasoconstricción pulmonar hipóxica exagerada y a la acumulación de líquido en el espacio alveolar. Mostramos que la hipertensión pulmonar hipóxica exagerada, per se, no es suficiente para producir un EPA, y que una alteración en la eliminación del fluido del espacio alveolar representa un segundo mecanismo fisiopatológico importante. Finalmente, describimos cómo los nuevos aportes obtenidos de los estudios del EPA pueden ser trasladados al manejo de otros estados patológicos ligados a la hipoxemia.


High altitude constitutes an exciting natural laboratory for medical research. Over the past decade, it has become clear that the results of high-altitude research may have important implications not only for the understanding of diseases in the millions of people living permanently at high altitude, but also for the treatment of hypoxemia-related disease states in patients living at low altitude. High-altitude pulmonary edema (HAPE) is a life-threatening condition occurring in predisposed, but otherwise healthy subjects, and, therefore, allows to study underlying mechanisms of pulmonary edema in humans, in the absence of confounding factors. Over the past decade, evidence has accumulated that HAPE results from the conjunction of two major defects, augmented alveolar fluid flooding resulting from exaggerated hypoxic pulmonary hypertension, and impaired alveolar fluid clearance related to defective respiratory transepithelial sodium transport. Here, after a brief presentation of the clinical features of HAPE, we review this novel concept. We provide experimental evidence for the novel concept that impaired pulmonary endothelial and epithelial nitric oxide synthesis and/or bioavailability may represent the central underlying defect predisposing to exaggerated hypoxic pulmonary vasoconstriction and alveolar fluid flooding. We demonstrate that exaggerated pulmonary hypertension, while possibly a condition sine qua non, may not be sufficient to cause HAPE, and how defective alveolar fluid clearance may represent a second important pathogenic mechanism. Finally, we outline how this insight gained from studies in HAPE may be translated into the management of hypoxemia related disease states in general.


Subject(s)
Humans , Altitude Sickness/physiopathology , Hypertension, Pulmonary/complications , Pulmonary Circulation , Pulmonary Edema/etiology , Sympathetic Nervous System , Altitude Sickness/complications , Altitude Sickness/drug therapy , Biological Availability , Biological Transport/physiology , Blood Pressure/drug effects , Blood Pressure/physiology , Epithelial Sodium Channels/physiology , Hypertension, Pulmonary/drug therapy , Hypertension, Pulmonary/physiopathology , Nitric Oxide/biosynthesis , Nitric Oxide/pharmacokinetics , Pulmonary Alveoli/drug effects , Pulmonary Circulation/physiology , Pulmonary Edema/drug therapy , Pulmonary Edema/physiopathology , Sodium/pharmacokinetics , Sodium/therapeutic use , Sympathetic Nervous System/physiopathology
3.
Article in English | IMSEAR | ID: sea-20919

ABSTRACT

In this study we have evaluated the role of bicarbonate on water and sodium transport in normal and secreting ilea of rabbits as controversy exists regarding the inclusion of bicarbonate in oral rehydration solution (ORS). In anaesthetized rabbits 10 cm closed ileal loops were constructed and filled with 5 ml of an electrolyte solution with and without bicarbonate, which contained polyethylene glycol (PEG; mol wt 4,000) as a non-absorbable marker. The fluid was withdrawn after an hour and analyzed for PEG, sodium and glucose. Similar studies were carried out in loops one hour after exposure to 1 microgram/ml of purified cholera toxin. Body temperature was maintained at 37 degrees C during the experiment by using a lamp. The mean +/- SE of water and sodium absorption, with bicarbonate versus without bicarbonate, was -1.4 +/- 0.1 vs -1.1 +/- 0.3 ml/h/10 cm, and -340.8 +/- 23.0 vs -308.4 +/- 35.6 mM/h/10 cm, respectively from secreting rabbit ilea. A similar effect was observed in normal ilea. It is concluded that bicarbonate containing electrolyte solution has no additional promoting effect on water and sodium absorption in normal or secreting ilea of rabbits.


Subject(s)
Animals , Bicarbonates/pharmacology , Biological Transport/drug effects , Glucose/pharmacokinetics , Intestines/metabolism , Male , Rabbits , Sodium/pharmacokinetics , Solutions , Water/metabolism
4.
Acta physiol. pharmacol. ther. latinoam ; 46(2): 103-10, 1996. tab, graf
Article in English | LILACS | ID: lil-172315

ABSTRACT

With the purpose studying the effectivity of an intratumoral single dose of chromic [(32)P] phosphate with great particles for the treatment of solid tumors, studies of biolimination, biodistribution and therapeutic action were carried out. Only for comparative purpose, similar studies were undertaken using a solution of sodium [(32)P] orthophosphategelatine. The results show that when sodium [(32)P] orthophosphategelatine is used, the percentage of total elimination is (85.90+8,70) per cent with a higler percentage in urine (64.50+13.70) per cent than in faeces (21.40+4.50) per cent. In biodistribution studies, the greater percentage is found in bone (15.54+2.21) per cent while only a (2.51+0.39) per cent remains in the tumor. When great particles chromic [(32)P] phosphate was intratumorally injected, we determined that the total elimination is equal (36.28+6.27) per cent, finding a higler amount in faeces (29.44+5.26) per cent than in urine (6.84+2.21) per cent. Biodistribution studies demonstrated that (49.82+5.41) per cent remains in the tumor and (9.63+4.89) per cent of the injected activity is found in the liver. On the other hand, when therapeutic action was evoluted, we observed that the percentage of tumor regression (P.T.R) is 52.0 per cent for the tumors injected with chromic [(32)P] phosphate and 0.0 per cent for those injected with sodium [(32)P] orthophosphate-gelatine. These results show that the great particles colloid of chromic [(32)P] phosphate is not safe enough for the tratment of solid tumors, since it is mobilezed from the injection point, delivering a high dose to the whole organism.


Subject(s)
Animals , Rats , Female , Adenocarcinoma/radiotherapy , Chromium Compounds/therapeutic use , Mammary Neoplasms, Experimental/radiotherapy , Phosphates/therapeutic use , Phosphorus Radioisotopes/therapeutic use , Sodium/therapeutic use , Chromium Compounds/administration & dosage , Chromium Compounds/pharmacokinetics , Colloids , Feces/chemistry , Injections , Phosphates/administration & dosage , Phosphates/pharmacokinetics , Phosphorus Radioisotopes/administration & dosage , Phosphorus Radioisotopes/pharmacokinetics , Rats, Sprague-Dawley , Remission Induction , Sodium/administration & dosage , Sodium/pharmacokinetics , Treatment Outcome , Urine/chemistry
5.
Arq. gastroenterol ; 32(1): 35-9, jan.-mar. 1995. ilus, graf
Article in English | LILACS | ID: lil-151648

ABSTRACT

Comentam-se alguns mecanismos complexos da absorçäo intestinal em relaçäo ao seu elo com interaçöes entre nutrientes, ou ao sistema alimentar, em si. Considera-se também a biodisponibilidade de nutrientes em relaçäo ao estado nutricional dos indivíduos, afim de enfatizar a necessidade de maior conhecimento da fisiologia para a melhor compreensäo da nutriçäo, e vice-versa


Subject(s)
Humans , Animals , Intestinal Absorption/physiology , Nutritional Sciences/physiology , Sodium/pharmacokinetics , Brazil , Calcium/pharmacokinetics , Cholera Toxin/pharmacology , Disaccharides/pharmacokinetics , Ion Transport/physiology , Intestinal Secretions , Intestinal Secretions/metabolism
6.
Rev. invest. clín ; 47(1): 63-79, ene.-feb. 1995. ilus
Article in Spanish | LILACS | ID: lil-149536

ABSTRACT

En este trabajo se analizan los factores renales y sistémicos involucrados en la retención de sodio y agua en dos condiciones: la depleción del volumen extracelular y los padecimientos que cursan con edema, especialmente la cirrosis hepática descompensada con ascitis. Se plantea que el estímulo sistémico, secundario a la pérdida de volumen del líquido corporal, ocurre a través del llamado volumen sanguíneo arterial efectivo (VAE) el cual disminuye por un déficit del volumen arterial secundario a una caída del gasto cardiaco o a un descenso en las resistencias arteriales vasculares periféricas. La reducción en el VAE estimula los baroceptores (especialemente los de alta presión, seno carotídeo y arco aórtico), los mecanismos intrarrenales (particularmente el aparato yuxtaglomerular) y simultáneamente incrementa la actividad simpático-adrenérgica sistémica, la liberación no osmótica de hormona antidiurética, la actividad del sistema renina-angiotensina aldosterona, las prostaglandinas y la endotelina, e inhible la liberación del péptido auricular natriurético. Además, se describen los mecanismos de transporte de sodio en los distintos segmentos de la nefrona y se analizan a la luz de lo que ocurre con ellos durante la depleción de volumen y en los padecimientos que cursan con edema, especialmente la cirrosis con ascitis Se especula que los mecanismos intrarrenales parecen ser más determinantes y persistentes que los mecanismos sistémicos en la retención de sodio y que posiblemente, esta ávida retención de sodio ocurre como resultado de un estímulo directo o por medio de los mensajeros (AMPc y GMPc) de los mecanismos enzimáticos y de los co y contra transportadores de los distintos segmentos tubulares de la nefrona. El estudio de las alteraciones en los transportadores del sodio, su clonación y reconocimiento estructural, permitirá reconocer, con precisión, los mecanismos intracelulares tubulares responsables de esta insaciable tendencia del cuerpo a conservar sodio. La información que se genere en el futuro ayudará a establecer los mecanismos íntimos de la retención de sodio en condiciones normales y patológicas, particularmente los padecimientos con edema, entre ellos, cirrosis hepática, síndrome nefrótico e insuficiencia cardiaca descompensada


Subject(s)
Dogs , Ascites/physiopathology , Liver Cirrhosis/physiopathology , Edema/physiopathology , Loop of Henle/metabolism , Loop of Henle/physiopathology , Renal Insufficiency/physiopathology , Sodium/pharmacokinetics , Water/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL